Pluristem Therapeutics Inc. (PSTI) Conducts Trials Showing Product Advancement
Pluristem Therapeutics works to commercialize cellular biotherapies for the treatment of several degenerative, ischemic and autoimmune conditions. In a release that was largely overlooked last week, Pluristem conveyed the success of recent clinical trials, showing the pronounced effectiveness of its PLacental eXpanded (PLX) cells in treating inflammatory bowel disease (IBD). Pluristem defines its PLX product as mesenchymal stromal cells (MSCs) that have been expanded using the company's proprietary PluriX™ 3-D bioreactor. Basically, MSCs are undifferentiated, protoplasmic placental cells. In the study, mice which were afflicted with IBD were administered PLX cells intrarectally, while a control group was treated with a…
